March 31 has a special meaning for our field: on this day in 1941, Iodine‑131 was used for the very first time in a patient, the spark that launched modern theranostics.

Today, we are at the World Theranostics Day event organized by the Oncidium foundation, celebrating this legacy and the global progress in targeted radiopharmaceuticals.

Many thanks to the organizers for the event and for spotlighting both clinical expertise and patient voices. Exchanges between patients and their physicians were especially insightful.

At MEDraysintell, we are proud to stand with the community and support innovation with the most comprehensive intelligence in radiotherapeutics and radiodiagnostics.

From the first I‑131 treatment to today’s expanding theranostics landscape, the journey continues, and we’re here for it.